Eltrombopag (REVOLADE FCT ALU) 30 Tablet
$760.00
REVOLADE FCT Tablet offers a valuable treatment option for patients with chronic immune thrombocytopenia (ITP) and chronic hepatitis C-related thrombocytopenia, providing effective platelet count management and reducing the risk of bleeding complications.
Description
REVLADAE FCT Tablet contains Eltrombopag in strengths of 25mg and 50mg, serving as a medication primarily prescribed for the treatment of thrombocytopenia (low platelet count) in patients with chronic immune thrombocytopenia (ITP) or chronic hepatitis C virus (HCV) infection.
Key Features:
- Thrombocytopenia Treatment: REVOLADE FCT Tablet is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP), a condition characterized by abnormally low platelet counts due to immune-mediated destruction of platelets.
- Eltrombopag Mechanism of Action: Eltrombopag, the active ingredient in REVOLADE, is a thrombopoietin receptor agonist that stimulates the production of platelets by binding to and activating the thrombopoietin receptor, thereby increasing platelet production and count.
- Chronic Hepatitis C Treatment: REVOLADE may also be used for the treatment of thrombocytopenia in patients with chronic hepatitis C virus (HCV) infection who are undergoing antiviral therapy, such as interferon-based regimens, where low platelet counts are a common side effect.
- Multiple Strengths: Available in two strengths (25mg and 50mg), allowing for individualized dosing based on factors such as platelet count, patient’s response to treatment, and tolerability.
- Fixed-Dose Tablet: REVOLADE FCT Tablet contains a fixed dose of Eltrombopag (25mg or 50mg) in each tablet, simplifying dosing and ensuring consistent medication delivery.
- Oral Administration: Administered orally, usually once daily, REVOLADE FCT Tablet offers convenient dosing for patients with thrombocytopenia, allowing them to take their medication at home.
- Clinical Efficacy: Clinical studies have demonstrated the efficacy of Eltrombopag in increasing platelet counts and reducing the risk of bleeding episodes in patients with chronic ITP and chronic hepatitis C-related thrombocytopenia.
- Potential Adverse Effects: Common side effects of REVOLADE may include headache, nausea, fatigue, diarrhea, and elevated liver enzymes. Patients should be monitored closely for adverse reactions and managed accordingly.
- Individualized Treatment Approach: The selection of REVOLADE as a treatment option for thrombocytopenia should be based on factors such as underlying disease etiology, platelet count, bleeding risk, patient’s overall health status, and treatment goals.
Additional information
strength | 25mg, 50mg |
---|
Only logged in customers who have purchased this product may leave a review.
Reviews
There are no reviews yet.